Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AbbVie Inc.
Advisory committee will discuss five types of toxicity risks with adeno-associated virus vector-based gene therapy products at a two-day meeting in September, which follows some recent high-profile instances of adverse events that have delayed development programs.
South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder. Plus deals involving Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.
The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.
Increased demand tied to COVID-19, plus supply chain difficulties, led to the blood collection device shortage, the US agency says.
- Other Names / Subsidiaries
- Pharmacyclics, Inc.
- Stemcentrx, Inc.